JP2018516254A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516254A5
JP2018516254A5 JP2017561653A JP2017561653A JP2018516254A5 JP 2018516254 A5 JP2018516254 A5 JP 2018516254A5 JP 2017561653 A JP2017561653 A JP 2017561653A JP 2017561653 A JP2017561653 A JP 2017561653A JP 2018516254 A5 JP2018516254 A5 JP 2018516254A5
Authority
JP
Japan
Prior art keywords
pyrimidin
amino
methanone
phenyl
benzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017561653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516254A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/052825 external-priority patent/WO2016193844A1/en
Publication of JP2018516254A publication Critical patent/JP2018516254A/ja
Publication of JP2018516254A5 publication Critical patent/JP2018516254A5/ja
Pending legal-status Critical Current

Links

JP2017561653A 2015-05-29 2016-05-16 バニン1酵素の阻害薬としての新規なヘテロ環化合物 Pending JP2018516254A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562167962P 2015-05-29 2015-05-29
US62/167,962 2015-05-29
US201562195005P 2015-07-21 2015-07-21
US62/195,005 2015-07-21
PCT/IB2016/052825 WO2016193844A1 (en) 2015-05-29 2016-05-16 Novel heterocyclic compounds as inhibitors of vanin-1 enzyme

Publications (2)

Publication Number Publication Date
JP2018516254A JP2018516254A (ja) 2018-06-21
JP2018516254A5 true JP2018516254A5 (enExample) 2019-05-23

Family

ID=56026933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017561653A Pending JP2018516254A (ja) 2015-05-29 2016-05-16 バニン1酵素の阻害薬としての新規なヘテロ環化合物

Country Status (5)

Country Link
US (2) US10308615B2 (enExample)
EP (1) EP3303303A1 (enExample)
JP (1) JP2018516254A (enExample)
CA (1) CA2987179C (enExample)
WO (1) WO2016193844A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3484876A1 (en) * 2016-07-14 2019-05-22 Pfizer Inc Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
US10961242B2 (en) * 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
AU2018285131B2 (en) * 2017-06-12 2021-11-11 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
WO2018231702A1 (en) 2017-06-13 2018-12-20 The Regents Of The University Of California Methods of improving cell-based therapy
US11497723B1 (en) * 2017-12-19 2022-11-15 Tony Antakly PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
US10702488B2 (en) * 2017-12-19 2020-07-07 Theriac Biomedical Inc. PPAR-γ activators, HDAC inhibitors and their therapeutical usages
WO2019133445A1 (en) * 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
AU2019326933B2 (en) * 2018-08-28 2024-12-05 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as Vanin inhibitors
WO2020102575A1 (en) * 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
MX2021006489A (es) * 2018-12-03 2021-07-06 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de vanina.
IL283397B2 (en) * 2018-12-03 2025-03-01 Boehringer Ingelheim Int Heteroaromatic compounds as vanin inhibitors
EA202191477A1 (ru) 2018-12-03 2021-10-13 Бёрингер Ингельхайм Интернациональ Гмбх Гетероароматические соединения в качестве ингибиторов ванина
CA3156136A1 (en) * 2019-11-07 2021-05-14 Michael Hadd Sodium-glucose linked transporter inhibitors for the management of chronic kidney disease, hypertension, and heart failure in companion animals
US12263144B2 (en) 2020-10-13 2025-04-01 Accubit LLC—Biotechnology Methods of treating IgA nephropathy with thiol-containing molecules
TWI811901B (zh) * 2020-12-17 2023-08-11 大陸商上海美悅生物科技發展有限公司 一種嘧啶甲醯胺類化合物及其應用
CN120247898A (zh) * 2025-03-31 2025-07-04 大连医科大学附属第二医院 一种噻吩甲酰胺类化合物及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ES2318899T3 (es) 1998-07-06 2009-05-01 Bristol-Myers Squibb Company Bifenil sulfonamidas como antagonistas duales de los receptores de angiotensina y endotelina.
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
DE602005015699D1 (de) 2004-05-12 2009-09-10 Pfizer Prod Inc Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
PL2463283T3 (pl) 2006-04-20 2014-10-31 Pfizer Prod Inc Skondensowane fenyloamidowe związki heterocykliczne do zapobiegania i leczenia chorób pośredniczonych przez glukokinazę
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
KR20090083956A (ko) 2006-11-29 2009-08-04 화이자 프로덕츠 인크. 스피로케톤 아세틸-CoA 카르복실라제 억제제
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
JP5435592B2 (ja) 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルCoAカルボキシラーゼ阻害剤
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
WO2010023594A1 (en) 2008-08-28 2010-03-04 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
UA99882C2 (uk) 2009-03-11 2012-10-10 Пфайзер Інк. Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
JP2012526097A (ja) 2009-05-08 2012-10-25 ファイザー・インク Gpr119調節因子
KR20120061063A (ko) 2009-06-05 2012-06-12 화이자 인코포레이티드 Gpr 119 조절제로서의 l-(피페리딘-4-일)-피라졸 유도체
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
PH12012502112A1 (en) * 2010-04-27 2021-06-23 Mitsubishi Tanabe Pharma Corp Novel amide derivative and use thereof as medicine
SG194847A1 (en) 2011-05-17 2013-12-30 Plexxikon Inc Kinase modulation and indications therefor
EP2736329A4 (en) 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
MX354965B (es) 2012-04-02 2018-03-27 Cytokinetics Inc Metodo para mejorar la funcion del diafragma.
US9585891B2 (en) * 2012-09-25 2017-03-07 Merck Patent Gmbh Alpha hydroxy amides

Similar Documents

Publication Publication Date Title
JP2018516254A5 (enExample)
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
RU2008141509A (ru) Mglur5 модуляторы 1
JP2010513304A5 (enExample)
RU2452738C2 (ru) Соединения, модулирующие активность c-fms и/или c-kit, и их применения
JP2014531465A5 (enExample)
RU2482111C2 (ru) Соединения, обладающие противораковой активностью
JP2007501189A5 (enExample)
RU2009125620A (ru) Органические соединения
CN115515947A (zh) Shp2抑制剂及其组合物和应用
JP2009519967A5 (enExample)
ME00427B (me) N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
JP2010514788A5 (enExample)
RU2015154987A (ru) Гетероциклические производные
JP2007519735A5 (enExample)
JP2006500348A5 (enExample)
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2005516934A5 (enExample)
JP2019524705A5 (enExample)
RU2014153626A (ru) Пиридиноновые и пиридазиноновые производные
JP2020526547A5 (enExample)
HRP20141190T1 (hr) Disupstituirani derivati piridina kao antikancerogena sredstva
RU2015143517A (ru) Пиразолсодержащие соединения и их применения
JP2008507564A5 (enExample)